Literature DB >> 31241755

Systemic Molecular Mediators of Inflammation Differentiate Between Crohn's Disease and Ulcerative Colitis, Implicating Threshold Levels of IL-10 and Relative Ratios of Pro-inflammatory Cytokines in Therapy.

Miranda G Kiernan1, J Calvin Coffey1,2, Shaheel M Sahebally1,2, Paul Tibbitts1,2, Emma M Lyons2, Eimear O'leary1, Funke Owolabi1, Colum P Dunne1.   

Abstract

BACKGROUND AND AIMS: Faecal diversion is associated with improvements in Crohn's disease but not ulcerative colitis, indicating that differing mechanisms mediate the diseases. This study aimed to investigate levels of systemic mediators of inflammation, including fibrocytes and cytokines, [1] in patients with Crohn's disease and ulcerative colitis preoperatively compared with healthy controls and [2] in patients with Crohn's disease and ulcerative colitis prior to and following faecal diversion.
METHODS: Blood samples were obtained from healthy individuals and patients with Crohn's disease or ulcerative colitis. Levels of circulating fibrocytes were quantified using flow cytometric analysis and their potential relationship to risk factors of inflammatory bowel disease were determined. Levels of circulating cytokines involved in inflammation and fibrocyte recruitment and differentiation were investigated.
RESULTS: Circulating fibrocytes were elevated in Crohn's disease and ulcerative colitis patients when compared with healthy controls. Smoking, or a history of smoking, was associated with increases in circulating fibrocytes in Crohn's disease, but not ulcerative colitis. Cytokines involved in fibrocyte recruitment were increased in Crohn's disease patients, whereas patients with ulcerative colitis displayed increased levels of pro-inflammatory cytokines. Faecal diversion in Crohn's disease patients resulted in decreased circulating fibrocytes, pro-inflammatory cytokines, and TGF-β1, and increased IL-10, whereas the inverse was observed in ulcerative colitis patients.
CONCLUSIONS: The clinical effect of faecal diversion in Crohn's disease and ulcerative colitis may be explained by differing circulating fibrocyte and cytokine responses. Such differences aid in understanding the disease mechanisms and suggest a new therapeutic strategy for inflammatory bowel disease. © European Crohn’s and Colitis Organisation (ECCO) 2019.

Entities:  

Keywords:  Inflammatory bowel disease; circulating fibrocytes; cytokines; faecal diversion

Year:  2020        PMID: 31241755     DOI: 10.1093/ecco-jcc/jjz117

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  5 in total

1.  Inflammatory bowel disease as a new risk factor for dementia.

Authors:  Marco Zuin; Roberto De Giorgio; Eleonora Capatti; Elisa Boschetti; Giovanni Zuliani
Journal:  Aging Clin Exp Res       Date:  2022-01-25       Impact factor: 3.636

Review 2.  Novel mechanisms and clinical trial endpoints in intestinal fibrosis.

Authors:  Jie Wang; Sinan Lin; Jonathan Mark Brown; David van Wagoner; Claudio Fiocchi; Florian Rieder
Journal:  Immunol Rev       Date:  2021-05-16       Impact factor: 10.983

3.  The Abilities of Salidroside on Ameliorating Inflammation, Skewing the Imbalanced Nucleotide Oligomerization Domain-Like Receptor Family Pyrin Domain Containing 3/Autophagy, and Maintaining Intestinal Barrier Are Profitable in Colitis.

Authors:  Jiuxi Liu; Jiapei Cai; Peng Fan; Naisheng Zhang; Yongguo Cao
Journal:  Front Pharmacol       Date:  2019-12-02       Impact factor: 5.810

4.  Mycobacterial Hsp65 antigen delivered by invasive Lactococcus lactis reduces intestinal inflammation and fibrosis in TNBS-induced chronic colitis model.

Authors:  Vanessa Pecini da Cunha; Tatiane Melo Preisser; Mariana Passos Santana; Denise Carmona Cara Machado; Vanessa Bastos Pereira; Anderson Miyoshi
Journal:  Sci Rep       Date:  2020-11-18       Impact factor: 4.379

5.  Adults with Crohn's disease exhibit elevated gynoid fat and reduced android fat irrespective of disease relapse or remission.

Authors:  Lisa Dowling; Philip Jakeman; Catherine Norton; Maeve M Skelly; Hamid Yousuf; Miranda G Kiernan; Margaret Toomey; Sheila Bowers; Suzanne S Dunne; J Calvin Coffey; Colum P Dunne
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.